⌘K
Loading ticker…
As of 2026-08-24, TransCode Therapeutics, Inc. Common Stock (RNAZ) has a 3-month relative strength percentile of 5 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 28. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 12.3%, relative volume 2.68×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
RNAZ is in a stage 4 downtrend, week 5. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -52.0% / -65.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
RNAZ appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $56K notional.
Held by 1 ETFs · $56K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $56K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RNAZ Jan avg: 21.33% median: 25.25% win: 75% σ: 88.13% n: 4 2022-04-12 → 2026-07-31 | RNAZ Feb avg: -25.30% median: -14.67% win: 50% σ: 35.73% n: 4 2022-04-12 → 2026-07-31 | RNAZ Mar avg: -30.88% median: -22.72% win: 0% σ: 32.44% n: 4 2022-04-12 → 2026-07-31 | RNAZ Apr avg: -9.37% median: -6.97% win: 0% σ: 5.36% n: 5 2022-04-12 → 2026-07-31 | RNAZ May avg: 10.01% median: -33.52% win: 20% σ: 101.99% n: 5 2022-04-12 → 2026-07-31 | RNAZ Jun avg: -16.89% median: -31.52% win: 40% σ: 32.21% n: 5 2022-04-12 → 2026-07-31 | RNAZ Jul avg: -9.61% median: -4.35% win: 40% σ: 43.06% n: 5 2022-04-12 → 2026-07-31 | RNAZ Aug avg: -16.96% median: -13.92% win: 0% σ: 12.09% n: 4 2022-04-12 → 2026-07-31 (current) | RNAZ Sep avg: 13.40% median: 1.07% win: 50% σ: 76.09% n: 4 2022-04-12 → 2026-07-31 | RNAZ Oct avg: -19.91% median: -22.46% win: 25% σ: 18.12% n: 4 2022-04-12 → 2026-07-31 | RNAZ Nov avg: -29.06% median: -29.35% win: 0% σ: 10.16% n: 4 2022-04-12 → 2026-07-31 | RNAZ Dec avg: -15.47% median: -29.74% win: 25% σ: 59.11% n: 4 2022-04-12 → 2026-07-31 |